Cizzle Biotechnology Holdings Plc
60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom
44 20 3934 6630
https://www.cizzlebiotechnology.com
版塊: Healthcare
行業: Biotechnology
全職員工: 4
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Allan John Syms | Executive Chairman | 無 | 無 | 1956 |
| Prof. Dawn Coverley | Founder, Chief Scientific Officer & Non-Executive Director | 無 | 無 | 1965 |
| Mr. Nigel R. Lee | Finance Director & Executive Director | 無 | 無 | 1961 |
| Mr. Morgan Williams | Head of Commercialisation for Yorkshire Cancer Research and Board Observer | 無 | 無 | 無 |
截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 GBp。
描述
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
公司管治
截至 無 止，Cizzle Biotechnology Holdings Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
